

IBS-D: A Case Study Approach to Improved Screening, and Detection

Anthony J. Lembo, MD

REFERENCES

American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*. 2009;104(Suppl 1):S1-35. <https://www.ncbi.nlm.nih.gov/pubmed/19521341>

Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. *Am J Gastroenterol*. 2014;109(10):1621-1630. doi: 10.1038/ajg.2014.215. <https://www.ncbi.nlm.nih.gov/pubmed/25070056>

Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin Epidemiol*. 2014; 6:71-80. <https://www.dovepress.com/the-epidemiology-of-irritable-bowel-syndrome-peer-reviewed-fulltext-article-CLEP>

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015;313(9): 949-958. <https://www.ncbi.nlm.nih.gov/pubmed/25734736>

Chey WD, Nojkov B, Rubenstein JH, Dobham RR, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. *Am J Gastroenterol*. 2010;105(4):859-865. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887227/>

Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. *Aliment Pharmacol Ther*. 2011;35(3): 350-359. doi: 10.1111/j.1365-2036.2011.04948.x. <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04948.x>


Ford AC, Chey WD, Tally NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of Diagnostic Tests for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome: Systematic Review and Meta-analysis. *Arch Int Med*. 2009;169(7):651-865. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108430>

Ford AC, Moayyedi P, Chey WD, et al; ACG Task Force on Management of Irritable Bowel Syndrome. ACG Task Force on IBS. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. 2018;113(Suppl 2):1-18. doi: 10.1038/s41395-018-0084-x. <https://www.ncbi.nlm.nih.gov/pubmed/29950604>

Grainek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. *Gastroenterology*. 2000;119(3):654-660. <https://www.ncbi.nlm.nih.gov/pubmed/10982758>

Hungin APS, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther*. 2005;21(11):1365-1375. <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2005.02463.x>

Lacy BE, Mearin F, Chang L et al. Bowel disorders. *Gastroenterology*. 2016;150(6):1393-1407.e5. [https://www.gastrojournal.org/article/S0016-5085\(16\)00222-5/abstract](https://www.gastrojournal.org/article/S0016-5085(16)00222-5/abstract)



IBS-D: A Case Study Approach to Improved Screening, and Detection

Anthony J. Lembo, MD

REFERENCES (cont'd)

Macaigne G, Lahmek P, Locher C, et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. *Am J Gastroenterol*. 2014;109(9):1461-1470. <https://www.ncbi.nlm.nih.gov/pubmed/25001258>

Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *Am J Gastroenterol*. 2015;110(3):444-454. <https://www.ncbi.nlm.nih.gov/pubmed/25732419>

Menees S, Saad R, Chey WD. Agents that act luminally to treat diarrhoea and constipation. *Nat Rev Gastroenterol Hepatol*. 2012;9(11):661-674. <https://www.ncbi.nlm.nih.gov/pubmed/22945441>

O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. *Br Med J*. 1990;300(6722):439-440. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1662249/pdf/bmj00166-0033.pdf>

Pimentel M, Morales W, Rezaie A, et al. Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. *PLoS ONE*. 2015;10:e0126438. doi.org/10.1371/journal.pone.0126438.

Rome IV Functional Gastrointestinal Disorders. 4th ed. Raleigh, NC: The Rome Foundation; 2016.

Saad R, Chey WD. Breath Testing for Small Intestinal Bacterial Overgrowth: Maximizing Test Accuracy. *Clin Gastroenterol Hepatol*. 2014;12(12):1964-1972; quiz e119-20. [https://www.cghjournal.org/article/S1542-3565\(13\)01468-7/fulltext](https://www.cghjournal.org/article/S1542-3565(13)01468-7/fulltext)

Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. *Gut*. 2013;62(1):159-176. doi: [10.1136/gutjnl-2012-302167](https://doi.org/10.1136/gutjnl-2012-302167)

Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. *Aliment Pharmacol Ther*. 2015;42(5):491-503. doi: 10.1111/apt.13283. <https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13283>

Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. *Gastroenterology*. 1995;109(6):1736-1741. <https://www.ncbi.nlm.nih.gov/pubmed/7498636>